Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Treatment Considerations Across the Bipolar Depression Spectrum

Listen as 2 experts in psychiatry discuss treatment strategies across the spectrum of bipolar depression—including in patients with comorbidities and patients at risk of developing bipolar depression—as well as their thoughts regarding phase-specific vs holistic treatment approaches.
Vladimir Maletic, MD
Greg W. Mattingly, MD
Released: October 6, 2022

In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, share their thoughts on treatment strategies across the bipolar depression spectrum. They begin by talking about their stance on treating bipolar with comorbidities with a holistic vs stepwise approach and discuss what strategies they would consider for a patient not yet diagnosed with but who is at risk of developing bipolar depression. In addition, they discuss the concept of phase-specific treatment, considerations for medication-related adverse events, and the utility of adjunctive measures for managing bipolar depression.

Information on this Educational Activity

Faculty

Vladimir Maletic, MD

Clinical Professor
Department of Psychiatry
USC School of Medicine
Greenville, South Carolina

Vladimir Maletic, MD: consultant/advisor/speaker: AbbVie, Alfasigma, Alkermes, Intra-Cellular, Janssen, Lundbeck, Otsuka, Sage, Supernus.
Greg W. Mattingly, MD

Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
Midwest Research Group
St. Louis, Missouri

Greg W. Mattingly, MD: speaker: AbbVie, Alkermes, Corium, Eisai, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Tris Pharma; consultant: AbbVie, Acadia, Alkermes, Axsome, Corium, Eisai, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neos, Neurocrine, Noven, Otsuka, Redax, Rhodes, Roche, Sage, Sirona, Sunovion, Supernus, Takeda, Teva, Tris Pharma; researcher: AbbVie, Acadia, Akili, Alkermes, Axsome, Boehringer, Emalex, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, NLS-1 Pharma AG, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, Teva.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Intra-Cellular Therapies, Inc.

Related Content

Downloadable slides from the major depressive disorder presentation at the 2022 Psychopharmacology Update conference (CCO)

Greg W. Mattingly, MD Released: December 1, 2022

Downloadable slides from the antidepressants presentation at the 8th Annual Psychopharmacology Update 2022 (CCO)

Anita Clayton, MD Released: December 1, 2022

Downloadable slides from the ADHD presentation at the 8th Annual Psychopharmacology Update 2022 (CCO)

Vladimir Maletic, MD Released: November 30, 2022

Downloadable slides from the LAI antipsychotics presentation at the 2022 Psychopharmacology Update conference, from Clinical Care Options (CCO)

Leslie Citrome, MD, MPH Released: November 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings